Eaton Bree R, Losken Albert, Okwan-Duodu Derick, Schuster David M, Switchenko Jeffrey M, Mister Donna, Godette Karen, Torres Mylin A
Department of Radiation Oncology, Emory University, Atlanta, GA, USA,
Ann Surg Oncol. 2014 Jan;21(1):93-9. doi: 10.1245/s10434-013-3235-8. Epub 2013 Oct 1.
The purpose of this study was to describe the incidence and location of ipsilateral breast tumor recurrence (IBTR) among breast cancer patients treated with oncoplastic reduction mammoplasty (ORM) and radiotherapy (RT).
The medical records of 86 consecutive women with ductal carcinoma in situ (DCIS) (n = 11) or invasive carcinoma of the breast (n = 75) treated with ORM at Emory University between January 1994 and December 2010 were reviewed.
Following ORM, prolonged wound healing or surgical complications led to delay of adjuvant chemotherapy or RT in 11 patients. Surgical clips were found outside the primary tumor breast quadrant in 43 % of the patients with available RT planning CT images. When the clips were found outside the primary tumor quadrant, the RT boost was more frequently delivered outside versus inside the primary tumor quadrant (67 vs. 33 %, p < 0.001). After a median follow-up period of 4.5 years (range 0.1-17.9), 6 patients developed an IBTR and only 1 IBTR occurred outside the primary tumor quadrant. The 5-year ipsilateral breast tumor control rates were 91 % (95 % CI 0.82-0.99) and 93 % (95 % CI 0.90-0.97) for patients with DCIS and invasive carcinoma, respectively.
The use of ORM yields acceptable rates of IBTR. ORM may displace breast tissue and surgical clips to breast quadrants outside of the original tumor location, but the majority of IBTRs still occur in the original tumor quadrant. This area remains at highest risk of in-breast recurrence in women treated with ORM irrespective of surgical clip location.
本研究旨在描述接受肿瘤整形性乳房缩小术(ORM)和放射治疗(RT)的乳腺癌患者同侧乳腺肿瘤复发(IBTR)的发生率及部位。
回顾了1994年1月至2010年12月在埃默里大学接受ORM治疗的86例连续的导管原位癌(DCIS)患者(n = 11)或浸润性乳腺癌患者(n = 75)的病历。
ORM术后,11例患者出现伤口愈合延长或手术并发症,导致辅助化疗或RT延迟。在有RT计划CT图像的患者中,43%的患者手术夹位于原发肿瘤乳腺象限之外。当手术夹位于原发肿瘤象限之外时,RT瘤床加量更常施于原发肿瘤象限之外而非之内(67%对33%,p < 0.001)。中位随访期4.5年(范围0.1 - 17.9年)后,6例患者发生IBTR,仅1例IBTR发生在原发肿瘤象限之外。DCIS和浸润性癌患者的5年同侧乳腺肿瘤控制率分别为91%(95%CI 0.82 - 0.99)和93%(95%CI 0.90 - 0.97)。
使用ORM可获得可接受的IBTR发生率。ORM可能会将乳腺组织和手术夹移位至原发肿瘤位置之外的乳腺象限,但大多数IBTR仍发生在原发肿瘤象限。无论手术夹位置如何,该区域仍是接受ORM治疗的女性乳腺内复发风险最高的部位。